American Society of Clinical Oncology

SHERPA: White

People

  1. Cercek Hanjis
    Cercek Hanjis
  2. Harding
    Harding
  3. Kemeny
    Kemeny
  4. Yaeger
    Yaeger
  5. Abou-Alfa
    Abou-Alfa
  6. Barker
    Barker
  7. Gollub
    Gollub
  8. Keohan
    Keohan
  9. Li
    Li
  10. Maki
    Maki

Groups

  1. Department of Medicine (7)
  2. Dermatology Service (7)
  3. Dermatology (7)
  4. Division of Subspecialty Medicine (7)
  5. Gastrointestinal Oncology Service (7)
  6. Solid Tumor Oncology Division (7)
  7. Survivorship Research (7)
  8. GSK Faculty (3)
  9. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (2)
  10. Center for Pancreatic Cancer Research (2)
Search Within
  1. "Gastrointestinal Oncology Service"
  2. "Mario Lacouture"
Formats
  1. Meeting Abstract (4)
  2. Journal Article (3)
Groups
  1. Department of Medicine (7)
  2. Dermatology (7)
  3. Dermatology Service (7)
  4. Division of Subspecialty Medicine (7)
  5. Gastrointestinal Oncology Service (7)
  6. Solid Tumor Oncology Division (7)

More Groups

People
  1. Mario Lacouture (7)
  2. Andrea Cercek Hanjis (2)
  3. James Harding (2)
  4. Jedd Wolchok (2)
  5. Nancy Kemeny (2)
  6. Paul Chapman (2)

More People

Years
  1. 2018 (1)
  2. 2017 (1)
  3. 2015 (2)
  4. 2014 (1)
  5. 2012 (1)
  6. 2011 (1)
Publications
  1. Journal of Clinical Oncology (6)
  2. JCO Precision Oncology (1)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Balancing RAF, MEK, and EGFR inhibitor doses to achieve clinical responses and modulate toxicity in BRAF V600E colorectal cancer
    Journal Article

    Mondaca, S.; Lacouture, M.; Hersch, J.; Yaeger, R.
    JCO Precision Oncology (2018)

    Fulltext@MSK | Save
  • First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study
    Meeting Abstract

    Li, B. T.; Janku, F.; Patel, M. R.; Sullivan, R. J.; Flaherty, K.; Buchbinder, E. I.; Lacouture, M. E.; Varghese, A. M.; Wong, D. J. L.; Sznol, M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase III randomized double-blind study of prophylactic topical dapsone 5% versus moisturizer for cetuximab-induced papulopustular (acneiform) rash
    Meeting Abstract

    Lacouture, M. E.; Belum, V. R.; Kehn, D.; Cercek, A.; Kemeny, N. E.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Pilot study of vemurafenib and panitumumab combination therapy in patients with BRAF V600E mutated metastatic colorectal cancer
    Meeting Abstract

    Yaeger, R. D.; Cercek, A.; O'Reilly, E. M.; Reidy, D. L.; Kemeny, N. E.; Wolinsky, T.; Gollub, M. J.; Lacouture, M. E.; Rosen, N.; Vakiani, E.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy
    Journal Article

    Harding, J. J.; Barker, C. A.; Carvajal, R. D.; Wolchok, J. D.; Chapman, P. B.; Lacouture, M. E.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Hypersensitivity skin reactions in melanoma patients treated with vemurafenib after ipilimumab therapy
    Meeting Abstract

    Harding, J. J.; Lacouture, M. E.; Pulitzer, M.; Callahan, M.; Postow, M. A.; Carvajal, R. D.; Wolchok, J. D.; Chapman, P. B.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Case series of dermatologic events associated with the insulin-like growth factor receptor 1 inhibitor cixutumumab
    Journal Article

    Daher, M.; Lacouture, M. E.; Rathkopf, D.; Maki, R. G.; Keohan, M. L.; Gansukh, B.; Chen, H.; Abou-Alfa, G. K.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save